A top 3 biopharma company sought deep dive evaluation of digital therapeutic trends and emerging innovation across 13 immunology indications
View Case StudyA top pharmaceutical company sought to evaluate emerging approaches in intracellular delivery and tissue-specific targeting of RNA/ASO molecules.
View Case StudyA biotechnology company launching an IV antibiotic wanted to track commercial uptake and differences in patient characteristics for those who received their drug vs. other treatments.
View Case StudyAcquiring company sought to probe the reimbursement landscape and innovative contracting considerations for a gene therapy in development.
View Case StudyA major pharmaceutical company asked us to assess emerging dermatology digital health solutions targeted to either patients or health care practitioners.
View Case StudyA mid-sized EU pharmaceutical company sought to track global threats to their psychiatric portfolio. They needed accurate and recurring risk assessments of emerging competitors based on clinical success and product overlap.
View Case StudyClient sought to understand reimbursement dynamics that might influence uptake for a postoperative pain medication (e.g. quality metrics, guidelines).
View Case StudyA vendor to the life sciences industry was launching a new product focused on value assessment for emerging pharmaceuticals and sought guidance around positioning and appropriate target audience.
View Case StudyA world-leading biotechnology company sought to understand epidemiology and subpopulation assumptions across a number of countries for various oncology tumor types.
View Case StudyA top 10 pharmaceutical company sought to examine unmet needs, reimbursement landscape (US, EU, Japan) and emerging competitors across 4 immunology therapeutic areas.
View Case Study